FDA Advisers Back Full Approval of Paxlovid for High-Risk Covid Treatment
TL;DR Summary
A panel of expert advisers to the FDA has endorsed Paxlovid as a treatment for adults with Covid who are at high risk for progression to severe illness. The drug significantly reduces hospitalizations and deaths among both unvaccinated and vaccinated people. While there are concerns about the "rebound" of Covid symptoms after taking the drug, the FDA concluded that there was not a significant difference in rebound rates between those who took Paxlovid and those who did not. The drug is likely to receive full approval soon.
- F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment The New York Times
- FDA advisers vote in support of Paxlovid approval for Covid-19 treatment in high-risk adults CNN
- COVID-19 treatment Paxlovid for high-risk adults close to full FDA approval WKRC TV Cincinnati
- AI-based drug interaction prediction technology analyzes the interaction between Paxlovid ingredients News-Medical.Net
- FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people CNBC
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
4 min
vs 5 min read
Condensed
90%
829 → 87 words
Want the full story? Read the original article
Read on The New York Times